Highly potent, anthracycline-based antibody-drug conjugates generated by enzymatic, site-specific conjugation

Molecular Cancer Therapeutics

Volumn 16, Issue 5, 2017, Pages 879-892

  Stefan, Nikolas ^a   Gébleux, Rémy ^a   Waldmeier, Lorenz ^a   Hell, Tamara ^a   Escher, Marie ^a   Wolter, Fabian I ^a   Grawunder, Ulf ^a   Beerli, Roger R ^a  

^a NBE Therapeutics AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBODY DRUG CONJUGATE; BACTERIAL ENZYME; BRENTUXIMAB VEDOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; PNU 159682 CAC10 ANTIBODY CONJUGATE; PNU 159682 MAYTANSINE CONJUGATE; PNU 159682 TRASTUZUMAB ANTIBODY CONJUGATE; SORTASE; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; 3'-DEAMINO-3'',4'-ANHYDRO-(2''-METHOXY-3''-OXY-4''-MORPHOLINYL)DOXORUBICIN; AMINOACYLTRANSFERASE; ANTHRACYCLINE; ANTIBODY CONJUGATE; BACTERIAL PROTEIN; CYSTEINE PROTEINASE; DOXORUBICIN; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY; SORTASE A; TRASTUZUMAB; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 8;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CHO CELL LINE; COMPARATIVE STUDY; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SORTASE MEDIATED ANTIBODY CONJUGATION; STAPHYLOCOCCUS AUREUS; TUMOR REGRESSION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG SCREENING; IMMUNOLOGY; NEOPLASM; TUMOR CELL LINE;

AMINOACYLTRANSFERASES; ANIMALS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; BACTERIAL PROTEINS; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; DOXORUBICIN; HUMANS; IMMUNOCONJUGATES; KI-1 ANTIGEN; MAYTANSINE; MICE; NEOPLASMS; RECEPTOR, ERBB-2; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020182253     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0688     Document Type: Article

References (50)

1. Schumacher D, Hackenberger CPR, Leonhardt H, Helma J. Current status: site-specific antibody drug conjugates. J Clin Immunol 2016;36:100-7.
2. Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev 2016;68:3-19.
3. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep 2015;35:e00225.
4. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000;14:1436-43.
5. Ohanian M, Kantarjian H, Guy D, Thomas D, Jabbour E, O'Brien S. Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. Expert Opin Biol Ther 2015;15: 601-11.
6. Ducry L, Stump B. Antibody drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010;21:5-13.
7. Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, et al. Disulfidelinked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011;22:717-27.
8. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
9. Doronina SO,Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24.
10. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68: 9280-90.
11. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 2008;19:759-65.
12. Fontaine SD, Reid R, Robinson L, Ashley GW, Santi DV. Long-term stabilization of maleimide-thiol conjugates. Bioconjug Chem 2015;26: 145-52.
13. Lyon RP, Setter JR, Bovee TD, Doronina SO, Hunter JH, Anderson ME, et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat Biotechnol 2014; 32:1059-62.
14. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs 2014;6:34-45.
15. van de Donk NWCJ, Dhimolea E. Brentuximab vedotin. MAbs 2012;4: 458-65.
16. Kim MT, Chen Y, Marhoul J, Jacobson F. Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. Bioconjug Chem 2014;25:1223-32.
17. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063-70.
18. Kang Y, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, van der Horst T, et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/ gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). J Clin Oncol 34, 2016(suppl 4S; abstr 5).
19. Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br J Haematol 2016;173:722-30.
20. Hallam TJ, Wold E, Wahl A, Smider VV. Antibody conjugates with unnatural amino acids. Mol Pharm 2015;12:1848-62.
21. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Sitespecific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925-32.
22. Strop P, Liu S-H, Dorywalska M, Delaria K, Dushin RG, Tran TT, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 2013;20:161-7.
23. Drake PM, Albers AE, Baker J, Banas S, Barfield RM, Bhat AS, et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug Chem 2014;25:1331-41.
24. Beerli RR, Hell T, Merkel AS, Grawunder U. Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS One 2015;10:e0131177.
25. Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
26. Perez EA, Hurvitz SA, Amler LC, Mundt KE, Ng V, Guardino E, et al. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res 2014;16:R50.
27. Yurkovetskiy AV, Yin M, Bodyak N, Stevenson CA, Thomas JD, Hammond CE, et al. A polymer-based antibody-vinca drug conjugate platform: characterization and preclinical efficacy. Cancer Res 2015;75:3365-72.
28. Li JY, Perry SR,Muniz-Medina V,Wang X,Wetzel LK, Rebelatto MC, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 2016;29:117-29.
29. Kung SutherlandMS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013;122:1455-63.
30. Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, et al. Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions. Clin Cancer Res 2015;21:4165-73.
31. MillerML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, et al. A new class of antibody-drug conjugateswith potent DNA alkylating activity.Mol Cancer Ther 2016;15:1870-8.
32. Junttila MR, MaoW, Wang X,Wang B-E, Pham T, Flygare J, et al. Targeting LGR5? cells with an antibody-drug conjugate for the treatment of colon cancer. Sci Transl Med 2015;7:314ra186-6.
33. Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, et al. A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clin Cancer Res 2015;21: 3298-306.
34. Quintieri L, Geroni C, Fantin M, Battaglia R, Rosato A, Speed W, et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res 2005;11: 1608-17.
35. Waldmeier L, Hellmann I, Gutknecht CK, Wolter FI, Cook SC, Reddy ST, et al. Transpo-mAb display: transposition-mediated B cell display and functional screening of full-length IgG antibody libraries. Mabs 2016;8: 726-40.
36. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 2013;65:157-70.
37. Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 2014;1845:84-9.
38. Mariani M, Capolongo L, Suarato A, Bargiotti A, Mongelli N, Grandi M, et al. Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR. Invest New Drugs 1994;12:93-7.
39. Danesi R, Agen C, Grandi M, Nardini V, Bevilacqua G, Del Tacca M. 3''-Deamino-3-''(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. Eur J Cancer 1993;29A:1560-5.
40. Chen I, Dorr BM, Liu DR. A general strategy for the evolution of bondforming enzymes using yeast display. Proc Natl Acad Sci U S A 2011; 108:11399-404.
41. Koninki K, Barok M, Tanner M, Staff S, Pitkanen J, Hemmila P, et al. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 2010;294: 211-9.
42. Zhang J, Cui X, Yan Y, Li M, Yang Y, Wang J, et al. Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity. AmJ Transl Res 2016;8:2862-75.
43. Oldham RK, Lewis M, Orr DW, Liao SK, Ogden JR, Avner B, et al. Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies. Mol Biother 1988;1:103-13.
44. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999;17:478-84.
45. van der Lee MMC, Groothuis PG, Ubink R, van der Vleuten MAJ, van Achterberg TA, Loosveld EM, et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther 2015; 14:692-703.
46. Casalini P, Iorio MV, Galmozzi E, Menard S. Role of HER receptors family in development and differentiation. J Cell Physiol 2004;200: 343-50.
47. Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, et al. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconj Chem 2015;26:650-9.
48. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012;30:184-9.
49. Dorywalska M, Dushin R, Moine L, Farias SE, Zhou D, Navaratnam T, et al. Molecular basis of valine-citrulline-PABC linker instability in sitespecific ADCs and its mitigation by linker design. Mol Cancer Ther 2016;15:958-70.
50. Dorywalska M, Strop P, Melton-Witt JA, Hasa-Moreno A, Farias SE, Galindo Casas M, et al. Site-dependent degradation of a non-cleavable auristatin-based linker-payload in rodent plasma and its effect on ADC efficacy. PLoS One 2015;10:e0132282.